Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 4 | 2024 | 262 | 1.470 |
Why?
|
| Pain | 11 | 2013 | 1696 | 0.800 |
Why?
|
| Analgesics | 3 | 2019 | 410 | 0.600 |
Why?
|
| Telemedicine | 2 | 2024 | 546 | 0.580 |
Why?
|
| Pandemics | 2 | 2024 | 1603 | 0.500 |
Why?
|
| Pain Management | 7 | 2021 | 715 | 0.490 |
Why?
|
| Analgesics, Opioid | 7 | 2019 | 1458 | 0.400 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2018 | 408 | 0.380 |
Why?
|
| Chondrosarcoma | 1 | 2013 | 213 | 0.370 |
Why?
|
| Practice Management | 1 | 2008 | 9 | 0.310 |
Why?
|
| Polypharmacy | 1 | 2008 | 63 | 0.300 |
Why?
|
| Hydrocodone | 2 | 2019 | 52 | 0.300 |
Why?
|
| Neurofeedback | 2 | 2018 | 20 | 0.290 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 664 | 0.290 |
Why?
|
| Neoplasms | 15 | 2021 | 15903 | 0.280 |
Why?
|
| Osteosarcoma | 1 | 2013 | 948 | 0.260 |
Why?
|
| Substance Abuse Detection | 2 | 2018 | 65 | 0.250 |
Why?
|
| Cancer Pain | 2 | 2021 | 344 | 0.240 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 508 | 0.220 |
Why?
|
| Opioid-Related Disorders | 3 | 2013 | 415 | 0.220 |
Why?
|
| Fentanyl | 2 | 2019 | 153 | 0.210 |
Why?
|
| Controlled Substances | 2 | 2019 | 14 | 0.180 |
Why?
|
| Sacroiliac Joint | 1 | 2019 | 19 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 1322 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 49 | 0.160 |
Why?
|
| Arthralgia | 1 | 2019 | 97 | 0.160 |
Why?
|
| Low Back Pain | 1 | 2019 | 84 | 0.160 |
Why?
|
| Pain Measurement | 5 | 2013 | 1017 | 0.150 |
Why?
|
| Fatigue | 4 | 2012 | 1280 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 274 | 0.140 |
Why?
|
| Dyspnea | 1 | 2019 | 421 | 0.130 |
Why?
|
| Nootropic Agents | 2 | 2007 | 32 | 0.130 |
Why?
|
| Indans | 2 | 2007 | 71 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2006 | 91 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 2 | 2006 | 196 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 517 | 0.110 |
Why?
|
| Paresthesia | 1 | 2013 | 33 | 0.110 |
Why?
|
| Pilot Projects | 6 | 2019 | 2853 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2013 | 90 | 0.110 |
Why?
|
| Injections, Spinal | 1 | 2013 | 275 | 0.100 |
Why?
|
| Middle Aged | 20 | 2019 | 90349 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2013 | 112 | 0.100 |
Why?
|
| Humans | 26 | 2024 | 271636 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2019 | 2431 | 0.100 |
Why?
|
| Survivors | 1 | 2017 | 1025 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 126 | 0.090 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 201 | 0.090 |
Why?
|
| Piperidines | 2 | 2007 | 1090 | 0.090 |
Why?
|
| Models, Educational | 1 | 2010 | 94 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 210 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2017 | 2099 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 355 | 0.080 |
Why?
|
| Adult | 14 | 2019 | 81791 | 0.080 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2008 | 48 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 14653 | 0.080 |
Why?
|
| Receptors, Muscarinic | 1 | 2008 | 72 | 0.080 |
Why?
|
| Vincristine | 1 | 2012 | 1572 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 28 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 917 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 513 | 0.080 |
Why?
|
| Female | 20 | 2019 | 148992 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 895 | 0.080 |
Why?
|
| Male | 20 | 2019 | 128836 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 286 | 0.070 |
Why?
|
| Curriculum | 1 | 2013 | 910 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 408 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 917 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2008 | 724 | 0.060 |
Why?
|
| Aged | 12 | 2019 | 73421 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2010 | 829 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2003 | 83 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 128 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 31032 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 2537 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2019 | 2619 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2018 | 505 | 0.050 |
Why?
|
| Treatment Outcome | 7 | 2018 | 33846 | 0.050 |
Why?
|
| Texas | 3 | 2019 | 6434 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 469 | 0.050 |
Why?
|
| Catheters | 1 | 2021 | 134 | 0.050 |
Why?
|
| Death | 1 | 2021 | 125 | 0.050 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 5919 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 2668 | 0.040 |
Why?
|
| Algorithms | 1 | 2011 | 3922 | 0.040 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Physicians | 2 | 2019 | 870 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 44 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 114 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2018 | 18 | 0.040 |
Why?
|
| Palliative Care | 1 | 2010 | 2156 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 423 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4502 | 0.040 |
Why?
|
| Neurons | 1 | 2008 | 2459 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 634 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2016 | 8 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2016 | 45 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9467 | 0.030 |
Why?
|
| Intention | 1 | 2016 | 113 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 179 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2021 | 39731 | 0.030 |
Why?
|
| Self Administration | 2 | 2006 | 58 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 265 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 22094 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 704 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 795 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 2051 | 0.030 |
Why?
|
| Thermosensing | 1 | 2012 | 9 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 1010 | 0.030 |
Why?
|
| Mechanoreceptors | 1 | 2012 | 29 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2021 | 13385 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 968 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2012 | 64 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2012 | 118 | 0.030 |
Why?
|
| Crime | 1 | 2012 | 31 | 0.030 |
Why?
|
| Touch | 1 | 2012 | 70 | 0.030 |
Why?
|
| Appetite | 1 | 2012 | 70 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2012 | 121 | 0.030 |
Why?
|
| Motor Skills | 1 | 2012 | 111 | 0.030 |
Why?
|
| Empathy | 1 | 2013 | 103 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 624 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2012 | 162 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 5102 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 12219 | 0.020 |
Why?
|
| Cancer Survivors | 1 | 2018 | 743 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 486 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 15254 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 790 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2013 | 6876 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 1100 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 542 | 0.020 |
Why?
|
| Oxotremorine | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anthracenes | 1 | 2008 | 47 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 42 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 13116 | 0.020 |
Why?
|
| Nickel | 1 | 2008 | 45 | 0.020 |
Why?
|
| Cadmium | 1 | 2008 | 47 | 0.020 |
Why?
|
| Biophysics | 1 | 2008 | 116 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2008 | 114 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 252 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2008 | 160 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2008 | 151 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 398 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 491 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 1284 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 584 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 446 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 2435 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 1742 | 0.020 |
Why?
|
| Risk Factors | 2 | 2013 | 18016 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3544 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 1325 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4251 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 2252 | 0.010 |
Why?
|
| Quality of Life | 1 | 2018 | 4745 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 225 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5856 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 2218 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 1594 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1965 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 1618 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 6633 | 0.010 |
Why?
|
| United States | 1 | 2016 | 16036 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6488 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 4193 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 6905 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 16226 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 62757 | 0.000 |
Why?
|